Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development

Therapeutic Innovation & Regulatory Science

Volumn 43, Issue 5, 2009, Pages 539-556

  Gaydos, Brenda ^a   Anderson, Keaven M ^b   Berry, Donald ^c   Burnham, Nancy ^d   Chuang Stein, Christy ^e   Dudinak, Jennifer ^a   Fardipour, Parvin ^a   Gallo, Paul ^a   Givens, Sam ^a   Lewis, Roger ^f   Maca, Jeff ^a   Pinheiro, José ^a   Pritchett, Yili ^g   Krams, Michael ^a  

^a Eli Lilly ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

^e PFIZER INC   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

Adaptive design; Best practices; Flexible design; Implementation; Planning

Indexed keywords

EID: 84996206874     PISSN: 21684790     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300503     Document Type: Article

References (16)

1. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Executive summary of the PhRMA Working Group on Adaptive Designs in Clinical Drug Development. J Biopharm Stat. 2006; 16: 275–283.
2. PhRMA Working Group on Adaptive Designs. Full white paper. Drug Inf J. 2006; 40: 421–484.
3. Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006; 40: 437–444.
4. Gaydos B, Krams M, Perevozskaya I, et al Adaptive dose response studies. Drug Inf J. 2006; 40: 451–461.
5. Bornkamp B, Bretz F, Dmitrienko A, et al Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007; 17: 965–995. Available at:http://biopharmnet.com/doc/doc12005.html.
6. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs—background, operational aspects, and examples. Drug Inf J. 2006; 4: 463–473.
7. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat. 1992; (A)21: 2833–2853.
8. Sandvik L, Erikssen J, Mowinckel P, Rodland EA. A method for determining the size of internal pilot studies. Stat Med. 1996; 15: 1587–1590.
9. Chuang-Stein C, Anderson K, Gallo P, Collins S. Sample size reestimation: a review and recommendations. Drug Inf J. 2006; 40: 475–484.
10. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J-M, Ford GA. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose response study of UK-279, 276 in acute ischemic stroke. Stroke. 2003; 34: 2543–2548.
11. Berry DA, Müller P, Grieve AP, et al Adaptive Bayesian designs for dose-ranging drug trials. In Gatsonis C, Carlin B, Carriquiry A, eds., Case Studies in Bayesian Statistics V: 99–181. New York: Springer-Verlag; 2001.
12. Berry DA. Bayesian clinical trials. Nature Rev Drug Discovery. 2006; 5: 27–36.
13. Gallo P, Chuang-Stein C. What should be the role of homogeneity testing in adaptive trials? Pharm Stat. 2009; 8: 1–4.
14. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med. 2005; 24: 3697–3714.
15. Brannath W, König F, Bauer P. Estimation in flexible two-stage designs. Stat Med. 2005; 25: 3366–3381.
16. Brannath W, Posch M, Bauer P. Recursive combination tests. J Am Stat Assoc. 2002; 97: 236–244.